Chronic heart failure
Conditions
Interventions
Administer sacbitril valsartan.
No administration of sacubitril-valsartan(Patients taking angiotensin converting enzyme inhibitor or angiotensin receptor blocker before this study should continue thes
Sponsors
Masuko Memorial Hospital
Department of Cardiology, Nagoya City University Graduate School of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with hemodialysis 2)Patients with heart failure 3)Patients who can give a written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients who had hypotension before or during the last 3-cycle hemodialysis 2)Hyperkalemia 3)Patients with severe liver disease 4)Patients with a history of hospitalization due to ischemic heart disease or stroke within 3 months. 5)Patients under an unstable heart failure condition 6)Patients with a life expectancy less than 1 year 7)Patients with acute phase disease requiring hospitalization 8)Patients with severe valvular disease 9)Patients with severe respiratory disease 10)Pregnant patients 11)Patients who are suspected of drug allergy to sacubitril-valsartan 12)Patients unable to communicate 13)Patients who are judged inappropriate for this study by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite endpoint (all cause death and hospitalizations for heart failure, ischemic heart disease, and stroke) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) BNP, ANP, NT-proBNP value at 1 month and 1 year. 2) Echocardiographic parameters at 1 and 2 years. 3) Adverse events in sacubitril-valsartan group. | — |
Countries
Japan
Contacts
Public ContactYoshihiro Seo
Masuko Memorial Hospital Department of cardiology
Outcome results
None listed